Contribute Try STAT+ Today

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal for weekend daydreams. Given that this is an extended break on this side of the pond, our agenda is slightly ambitious. We plan to tackle numerous chores around the Pharmalot grounds, stroll endlessly with the official mascot, and check in on the Pharmalot ancestors. And what about you. This is a fine time to enjoy outdoor cooking, a visit to a beach or lake, or frolicking about a garden. You might also catch up on your reading or reach out to someone special. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …

GlaxoSmithKline (GSK) rejected demands by the hedge fund Elliott Management for the company to change its board and sell its consumer health care arm after separating it from its pharma business, a day after strongly worded proposals from the activist investor, Reuters writes. The board also maintained that support for Glaxo’s strategy and leadership was shown in talks with its largest shareholders. In a letter to the board on Thursday, Elliott argued Glaxo should review its leadership and consider a sale of its consumer health care business.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment